# Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

> **NCT03959189** · PHASE1 · COMPLETED · sponsor: **Expansion Therapeutics, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Myotonic Dystrophy, Type 1 (DM1)
- Myotonic Dystrophy

## Interventions

- **DRUG:** ERX-963
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03959189
- **Lead sponsor:** Expansion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-04-30
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959189, "Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03959189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*